NO20043829L - Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel - Google Patents
Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddelInfo
- Publication number
- NO20043829L NO20043829L NO20043829A NO20043829A NO20043829L NO 20043829 L NO20043829 L NO 20043829L NO 20043829 A NO20043829 A NO 20043829A NO 20043829 A NO20043829 A NO 20043829A NO 20043829 L NO20043829 L NO 20043829L
- Authority
- NO
- Norway
- Prior art keywords
- hemicalsium
- atorvastatin
- organic solvent
- essentially free
- desolvating
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 239000003960 organic solvent Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35849702P | 2002-02-19 | 2002-02-19 | |
| PCT/US2003/005216 WO2003070665A2 (en) | 2002-02-19 | 2003-02-19 | Desolvating solvates of atorvastatin hemi-calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043829L true NO20043829L (no) | 2004-09-13 |
Family
ID=27757749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043829A NO20043829L (no) | 2002-02-19 | 2004-09-13 | Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7122681B2 (enExample) |
| EP (1) | EP1465901A4 (enExample) |
| JP (4) | JP4422488B2 (enExample) |
| KR (3) | KR20090045420A (enExample) |
| CN (1) | CN100379723C (enExample) |
| AU (1) | AU2003213171A1 (enExample) |
| CA (1) | CA2475123A1 (enExample) |
| HR (1) | HRP20040767A2 (enExample) |
| IL (1) | IL163594A0 (enExample) |
| IS (1) | IS7407A (enExample) |
| MX (1) | MXPA04007995A (enExample) |
| NO (1) | NO20043829L (enExample) |
| PL (1) | PL372241A1 (enExample) |
| WO (1) | WO2003070665A2 (enExample) |
| ZA (1) | ZA200406229B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| JP2007505944A (ja) * | 2004-07-22 | 2007-03-15 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウム及びその調製の方法 |
| CA2578370A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Inc. | Triazolobenzodiazepines and their use as vasopressin antagonists |
| CA2582449A1 (en) * | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Amorphous atorvastatin calcium |
| WO2006106372A1 (en) * | 2005-04-08 | 2006-10-12 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New crystalline atorvastatin hemicalcium salt polymorph form |
| CA2633268A1 (en) * | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| EP3585783A2 (en) * | 2016-02-25 | 2020-01-01 | Asceneuron SA | Sulfoximine glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| EP3841093B1 (en) | 2018-08-22 | 2023-06-21 | Asceneuron SA | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US444129A (en) * | 1891-01-06 | Henry l | ||
| US4444129A (en) * | 1982-11-05 | 1984-04-24 | Lecorp | Method of drying fine coal particles |
| DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
| JPS59167676A (ja) * | 1983-03-11 | 1984-09-21 | 株式会社 大川原製作所 | 多室型流動層乾燥機 |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| KR100431038B1 (ko) * | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| CZ20021642A3 (cs) | 1999-11-17 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy atorvastatinu vápenatého |
| EP1237865B1 (en) | 1999-12-17 | 2005-11-16 | Pfizer Science and Technology Ireland Limited | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
| WO2001044181A1 (en) | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| CZ20031495A3 (cs) * | 2000-11-03 | 2004-01-14 | Teva Pharmaceutical Industries Ltd. | Forma VII hemi-kalcium atorvastatinu |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2002224952B2 (en) | 2000-12-27 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| IN190564B (enExample) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| SK16002003A3 (sk) * | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| RU2304139C2 (ru) | 2001-07-30 | 2007-08-10 | Д-р Редди'с Лабораторис Лтд | Кристаллические формы vi и vii кальциевой соли аторвастатина |
| WO2003018547A2 (en) | 2001-08-31 | 2003-03-06 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| MXPA04007939A (es) | 2002-02-15 | 2004-11-26 | Teva Pharma | Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix. |
-
2003
- 2003-02-19 MX MXPA04007995A patent/MXPA04007995A/es active IP Right Grant
- 2003-02-19 KR KR1020097007465A patent/KR20090045420A/ko not_active Ceased
- 2003-02-19 KR KR1020097007464A patent/KR20090045419A/ko not_active Ceased
- 2003-02-19 IL IL16359403A patent/IL163594A0/xx unknown
- 2003-02-19 CA CA002475123A patent/CA2475123A1/en not_active Abandoned
- 2003-02-19 EP EP03709217A patent/EP1465901A4/en not_active Withdrawn
- 2003-02-19 HR HRP20040767 patent/HRP20040767A2/hr not_active Application Discontinuation
- 2003-02-19 JP JP2003569575A patent/JP4422488B2/ja not_active Expired - Fee Related
- 2003-02-19 KR KR10-2004-7012804A patent/KR20040086397A/ko not_active Ceased
- 2003-02-19 CN CNB038040913A patent/CN100379723C/zh not_active Expired - Fee Related
- 2003-02-19 AU AU2003213171A patent/AU2003213171A1/en not_active Abandoned
- 2003-02-19 PL PL03372241A patent/PL372241A1/xx unknown
- 2003-02-19 US US10/370,424 patent/US7122681B2/en not_active Expired - Fee Related
- 2003-02-19 WO PCT/US2003/005216 patent/WO2003070665A2/en not_active Ceased
-
2004
- 2004-08-04 ZA ZA200406229A patent/ZA200406229B/en unknown
- 2004-08-17 IS IS7407A patent/IS7407A/is unknown
- 2004-09-13 NO NO20043829A patent/NO20043829L/no not_active Application Discontinuation
-
2006
- 2006-10-02 US US11/542,339 patent/US20070027328A1/en not_active Abandoned
-
2009
- 2009-02-26 JP JP2009044173A patent/JP2009143957A/ja active Pending
- 2009-07-17 JP JP2009169170A patent/JP2009235100A/ja active Pending
-
2013
- 2013-03-13 JP JP2013050939A patent/JP2013136630A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040086397A (ko) | 2004-10-08 |
| JP4422488B2 (ja) | 2010-02-24 |
| JP2009235100A (ja) | 2009-10-15 |
| IL163594A0 (en) | 2005-12-18 |
| HRP20040767A2 (en) | 2004-12-31 |
| EP1465901A4 (en) | 2006-02-01 |
| AU2003213171A1 (en) | 2003-09-09 |
| CN1633439A (zh) | 2005-06-29 |
| JP2013136630A (ja) | 2013-07-11 |
| CA2475123A1 (en) | 2003-08-28 |
| PL372241A1 (en) | 2005-07-11 |
| WO2003070665A3 (en) | 2004-02-12 |
| CN100379723C (zh) | 2008-04-09 |
| KR20090045419A (ko) | 2009-05-07 |
| WO2003070665A2 (en) | 2003-08-28 |
| US7122681B2 (en) | 2006-10-17 |
| JP2005523285A (ja) | 2005-08-04 |
| EP1465901A2 (en) | 2004-10-13 |
| JP2009143957A (ja) | 2009-07-02 |
| IS7407A (is) | 2004-08-17 |
| US20030216584A1 (en) | 2003-11-20 |
| MXPA04007995A (es) | 2004-11-26 |
| US20070027328A1 (en) | 2007-02-01 |
| ZA200406229B (en) | 2006-06-28 |
| KR20090045420A (ko) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL163594A0 (en) | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent | |
| DE60316841D1 (de) | Triazolderivate als inhibitoren von11-beta-hydroxysteroid-dehydrogenase-1 | |
| ATE398105T1 (de) | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase | |
| DE60321808D1 (de) | Flavon derivate als inhibitoren von cyclin-abhängigen kinasen | |
| DK1644384T3 (da) | Fremgangsmåde og mellemprodukter til syntese af entecavir | |
| NO20033491D0 (no) | Heterocykliske inhibitorer av ERK2 og anvendelser derav | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| NO20024920D0 (no) | Kombinasjon av organiske forbindelser | |
| DK1487846T3 (da) | Fremgangsmåde til forbedring af renged og udbytte af sucralose | |
| NO20050636L (no) | Inhibitorer av tyrosinkinaser | |
| DE60234167D1 (de) | Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren | |
| NO20022249D0 (no) | Fremgangsmåte for forbehandling av naturgass inneholdende sure forbindelser | |
| DE60332036D1 (de) | Einteilige hand-airbrush | |
| SE0303102L (sv) | Realtidsanalys av gasblandningar | |
| ITMI20021391A1 (it) | Nitroderivati di inibitori della cicloossigenasi-2 | |
| NO20045660L (no) | N-((3okso-2,3-dihydro-IH-isoindol-1-yl)acetyl)guanidinderivater som NHE-1-inhibitorer for behandling av infarkt og angina pectoris | |
| EA200300925A1 (ru) | Новый способ промышленного синтеза ранелата стронция и его гидратов | |
| EP1539248A4 (en) | INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER | |
| NO20041187L (no) | Metoder og blandinger av nye triazinforbindelser | |
| HRP20060124A2 (en) | Process for the preparation of n-amino substituted heterocyclic compounds | |
| AU2003207342A1 (en) | Cleaning device for cleaning of metal strings of musical instruments | |
| NO994873D0 (no) | Metode for syntese og analyse av kombinatoriske kjemibiblioteker | |
| NO20033488D0 (no) | Prövetaking av hydrokarboner fra geologiske formasjoner | |
| ITMI20031451A1 (it) | Derivati diidro-ftalazinici inibitori della fosfodiesterasi 4 | |
| NO20072431L (no) | Fremgangsmate og intermediater for fremstilling av N-(1-benzohydryl-azetidin-3-yl-)-N-fenyl-metylsulfonamid-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |